CA2614529C - Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone thyroidienne - Google Patents

Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone thyroidienne Download PDF

Info

Publication number
CA2614529C
CA2614529C CA2614529A CA2614529A CA2614529C CA 2614529 C CA2614529 C CA 2614529C CA 2614529 A CA2614529 A CA 2614529A CA 2614529 A CA2614529 A CA 2614529A CA 2614529 C CA2614529 C CA 2614529C
Authority
CA
Canada
Prior art keywords
isopropyl
phenyl
pyridazin
dichloro
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2614529A
Other languages
English (en)
Other versions
CA2614529A1 (fr
Inventor
Nancy-Ellen Haynes
Denis John Kertesz
Sherrie Lynn Pietranico-Cole
Yimin Qian
Nathan Robert Scott
Sung-Sau So
Kshitij Chhabilbhai Thakkar
Jefferson Wright Tilley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2614529A1 publication Critical patent/CA2614529A1/fr
Application granted granted Critical
Publication of CA2614529C publication Critical patent/CA2614529C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés de la formule (I) et des sels pharmaceutiquement acceptables de ces derniers, les substituants étant tels que mentionnés dans la description. Les composés précités, et les compositions pharmaceutiques les contenant, sont utilisés dans le traitement de maladies telles que l'obésité, l'hyperlipidémie, l'hypercholestérolémie et le diabète et autres affections et maladies liées, et peuvent être utilisés pour d'autres maladies telles que la stéato-hépatite non alcoolique (NASH), l'athérosclérose, les maladies cardiovasculaires, l'hypothyroïdie, le cancer de la thyroïde et autres affections et maladies liées.
CA2614529A 2005-07-21 2006-07-11 Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone thyroidienne Active CA2614529C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70121505P 2005-07-21 2005-07-21
US60/701,215 2005-07-21
PCT/EP2006/064093 WO2007009913A1 (fr) 2005-07-21 2006-07-11 Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone thyroidienne

Publications (2)

Publication Number Publication Date
CA2614529A1 CA2614529A1 (fr) 2007-01-25
CA2614529C true CA2614529C (fr) 2011-06-28

Family

ID=37114368

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2614529A Active CA2614529C (fr) 2005-07-21 2006-07-11 Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone thyroidienne

Country Status (32)

Country Link
US (3) US7452882B2 (fr)
EP (1) EP1919878B1 (fr)
JP (1) JP5000649B2 (fr)
KR (1) KR100965006B1 (fr)
CN (1) CN101228135B (fr)
AR (1) AR054848A1 (fr)
AT (1) ATE480524T1 (fr)
AU (1) AU2006271721C1 (fr)
BR (1) BRPI0613754B8 (fr)
CA (1) CA2614529C (fr)
CR (1) CR9644A (fr)
CY (1) CY1110929T1 (fr)
DE (1) DE602006016821D1 (fr)
DK (1) DK1919878T3 (fr)
EC (1) ECSP088120A (fr)
ES (1) ES2349131T3 (fr)
HK (1) HK1115129A1 (fr)
HR (1) HRP20100633T1 (fr)
IL (1) IL188476A (fr)
MA (1) MA29731B1 (fr)
MX (1) MX2008000818A (fr)
MY (1) MY142861A (fr)
NO (1) NO340679B1 (fr)
NZ (1) NZ565190A (fr)
PL (1) PL1919878T3 (fr)
PT (1) PT1919878E (fr)
RS (1) RS51639B (fr)
RU (1) RU2379295C2 (fr)
TW (1) TWI330636B (fr)
UA (1) UA88104C2 (fr)
WO (1) WO2007009913A1 (fr)
ZA (1) ZA200800405B (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512359A (ja) 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
EP1604988A1 (fr) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Dérivés de pyridazinone, méthodes de leur préparation et leur utilisation comme pharmaceutiques
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
ATE480524T1 (de) 2005-07-21 2010-09-15 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
CA2666193A1 (fr) 2006-08-08 2008-02-14 Sanofi-Aventis Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituee, son procede de fabrication, medicament contenant ce compose et son utilisation
WO2008133141A1 (fr) * 2007-04-24 2008-11-06 Toyo Boseki Kabushiki Kaisha Protéine recombinante d'osmotine, son procédé de fabrication et son utilisation
PL2061766T3 (pl) * 2007-06-06 2011-02-28 Torrent Pharmaceuticals Ltd Nowe związki
US8076334B2 (en) * 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
JP5758630B2 (ja) 2007-11-15 2015-08-05 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Ｐａｒｐ阻害剤としてのピリダジノン誘導体
KR100981781B1 (ko) 2008-02-29 2010-09-10 재단법인 한국원자력의학원 방사선 치료용 콜리메이터 장치 및 그 장치를 이용한방사선 치료장치
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
WO2010122980A1 (fr) 2009-04-20 2010-10-28 田辺三菱製薬株式会社 Nouvel agoniste du récepteur ss de l'hormone thyroïdienne
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
JP5847533B2 (ja) * 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
SG10202006058QA (en) * 2012-09-17 2020-08-28 Madrigal Pharmaceuticals Inc Method of synthesizing thyroid hormone analogs and polymorphs thereof
CN105272927A (zh) * 2015-11-17 2016-01-27 华中药业股份有限公司 一种制备氯氮卓的新方法
KR20230156159A (ko) 2016-10-18 2023-11-13 마드리갈 파마슈티칼스, 인크. Thr-베타 아고니스트로 간 질환 또는 지질 질환을 치료하는 방법
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
CA3075877A1 (fr) 2017-09-14 2019-03-21 Riken Procede de production de tissus retiniens
JP7156722B2 (ja) * 2018-01-23 2022-10-19 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピリダジノン化合物
CA3095872A1 (fr) 2018-04-16 2019-10-24 Ioulia Tseti Composition pharmaceutique de poudre seche pour inhalation comprenant une hormone thyroidienne
CN111801324B (zh) * 2018-06-12 2021-10-22 四川海思科制药有限公司 甲状腺激素受体激动剂及其用途
US20210292304A1 (en) * 2018-06-22 2021-09-23 Hinova Pharmaceuticals Inc. Deuterated mgl-3196 compound and use thereof
AR115666A1 (es) * 2018-07-02 2021-02-10 Madrigal Pharmaceuticals Inc Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo
US10800767B2 (en) 2018-08-24 2020-10-13 Terns, Inc. Thyroid hormone receptor beta agonist compounds
JP2022500366A (ja) * 2018-09-06 2022-01-04 ガルメド リサーチ アンド ディベロップメント リミテッド 肝疾患治療のための併用療法
EP3863635A4 (fr) 2018-10-12 2022-06-15 Terns, Inc. Composés agonistes du récepteur bêta des hormones thyroïdiennes
CA3113373A1 (fr) * 2018-10-12 2020-04-16 InventisBio Co., Ltd. Agonistes du recepteur des hormones thyroidiennes
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111592528A (zh) * 2019-02-20 2020-08-28 苏州泽璟生物制药股份有限公司 氘代的哒嗪酮及其衍生物和药物组合物
CN113474335A (zh) * 2019-02-21 2021-10-01 南京瑞捷医药科技有限公司 新型化合物及其作为甲状腺激素受体激动剂的用途
SG11202109855PA (en) 2019-03-13 2021-10-28 Sumitomo Dainippon Pharma Co Ltd Method for evaluating quality of transplant neural retina, and transplant neural retina sheet
WO2020227549A1 (fr) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATEURS DE THR-β ET LEURS PROCÉDÉS D'UTILISATION
CN111909137B (zh) * 2019-05-10 2023-05-30 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
CN114174282A (zh) * 2019-05-29 2022-03-11 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
WO2021032218A1 (fr) 2019-08-19 2021-02-25 苏州闻天医药科技有限公司 COMPOSÉ AGONISTE DU RÉCEPTEUR THR-β HÉTÉROCYCLIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
CN112409340B (zh) * 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
CA3154488A1 (fr) * 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Composes agonistes du recepteur beta de l'hormone thyroidienne
WO2021043185A1 (fr) * 2019-09-04 2021-03-11 Sunshine Lake Pharma Co., Ltd. Composé utilisé comme agoniste du récepteur bêta des hormones thyroïdiennes et son utilisation
EP4028008A4 (fr) * 2019-09-12 2023-09-13 Terns Pharmaceuticals, Inc. Composés agonistes du récepteur bêta de l'hormone thyroïdienne
JP2022549009A (ja) * 2019-09-24 2022-11-22 ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 甲状腺ホルモンベータ受容体アゴニストとしての化合物及びその使用
CN112707892A (zh) * 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
EP4083024A4 (fr) * 2019-11-26 2023-11-01 KPC Pharmaceuticals, Inc. Composé de 1,2,4-triazine-3,5-dione, son procédé de préparation et son utilisation
CN114787153A (zh) * 2019-12-26 2022-07-22 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN113045551A (zh) * 2019-12-27 2021-06-29 广东东阳光药业有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
US11780825B2 (en) 2020-01-13 2023-10-10 Eccogene (Shanghai) Co., Ltd. Thyroid hormone receptor agonists and use thereof
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
CN113698388B (zh) * 2020-05-20 2022-11-22 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
JP2023528637A (ja) 2020-06-02 2023-07-05 成都康弘▲葯▼▲業▼集▲團▼股▲フン▼有限公司 新規甲状腺ホルモンβ受容体アゴニスト
WO2022041026A1 (fr) * 2020-08-27 2022-03-03 InventisBio Co., Ltd. Composés de pyridazinone
WO2022053028A1 (fr) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 Composé de 1,2,4-triazine-3,5-(2h,4h)-dicétone et son utilisation
EP4286377A1 (fr) * 2020-09-10 2023-12-06 Crystal Pharmaceutical (Suzhou) Co., Ltd. Forme cristalline de resmetirom, son procédé de préparation et son utilisation
WO2022054924A1 (fr) 2020-09-11 2022-03-17 大日本住友製薬株式会社 Milieu pour tissu destiné à la transplantation
US20230313133A1 (en) 2020-09-11 2023-10-05 Riken Complex Containing Neural Retina-Containing Cell Aggregates and Matrix, and Method for Manufacturing Same
TW202220977A (zh) * 2020-09-30 2022-06-01 大陸商江蘇恆瑞醫藥股份有限公司 ６－側氧－１，６－二氫噠嗪類衍生物、其製備方法及其在醫藥上的應用
US20230364099A1 (en) 2020-10-19 2023-11-16 Teva Pharmaceuticals International Gmbh Solid state forms of resmetirom
CA3197249A1 (fr) * 2020-11-06 2022-05-12 David Craig Mcgowan Pyridazinones bicycliques comme beta-agonistes du recepteur des hormones thyroidiennes
CN112645936B (zh) 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
CN114685450A (zh) * 2020-12-30 2022-07-01 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
WO2024084491A1 (fr) * 2022-10-21 2024-04-25 Mehta Nilesh Vipinchandra Procédé de synthèse de res metirom et de ses intermédiaires
CN115650928B (zh) * 2022-12-28 2023-03-31 凯思凯旭(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582842A (en) * 1981-02-25 1986-04-15 Merck & Co., Inc. Anti-asthmatic 6H-dibenz-[b,e] [1,4]oxathiepin derivatives, compositions, and method of use therefor
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
AU4440596A (en) 1995-02-10 1996-08-22 Smithkline Beecham Corporation Use of hcp SH2 specific compounds to enhance erythropoiesis
HU224495B1 (hu) 1995-06-06 2005-10-28 Pfizer Inc. Eljárás 2-(aril-oxi)-4-klór-piridin-származékok előállítására
AU6480796A (en) 1995-06-30 1997-02-05 Smithkline Beecham Corporation Use of stat 6 sh2 domain specific compounds to treat allergic reactions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
GB9713739D0 (en) * 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
AR023659A1 (es) 1998-09-18 2002-09-04 Vertex Pharma Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
TR200102561T2 (tr) * 1999-03-01 2002-02-21 Pfizer Products Inc. Tiroid alıcı ligantları olarak oksamik asitler ve türevleri
CA2433100A1 (fr) * 2000-12-27 2002-07-04 Helmut Haning Derives de l'indole utilises comme ligands de recepteurs de la thyroide
EP1358175A2 (fr) * 2001-02-08 2003-11-05 Karo Bio Ab Nouveaux ligands de recepteurs thyroidiens
EP1236720B1 (fr) * 2001-02-28 2005-06-15 Pfizer Products Inc. Derives de sulfonyl-pyridazinone comme inhibiteurs de reductase d'aldose
JP2007512359A (ja) 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
CN1934092A (zh) * 2004-03-23 2007-03-21 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
ATE480524T1 (de) 2005-07-21 2010-09-15 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten

Also Published As

Publication number Publication date
RS51639B (en) 2011-10-31
PL1919878T3 (pl) 2011-03-31
NO20080058L (no) 2008-04-18
DK1919878T3 (da) 2010-10-25
US7452882B2 (en) 2008-11-18
DE602006016821D1 (de) 2010-10-21
AU2006271721B2 (en) 2010-06-17
RU2008106058A (ru) 2009-08-27
MX2008000818A (es) 2008-03-18
ECSP088120A (es) 2008-02-20
MA29731B1 (fr) 2008-09-01
UA88104C2 (ru) 2009-09-10
EP1919878A1 (fr) 2008-05-14
BRPI0613754B1 (pt) 2021-03-16
HRP20100633T1 (hr) 2011-01-31
BRPI0613754A2 (pt) 2011-02-08
NZ565190A (en) 2010-02-26
WO2007009913A1 (fr) 2007-01-25
USRE46024E1 (en) 2016-06-07
CR9644A (es) 2008-02-20
ZA200800405B (en) 2008-12-31
CY1110929T1 (el) 2015-06-10
KR100965006B1 (ko) 2010-06-21
BRPI0613754B8 (pt) 2021-05-25
ATE480524T1 (de) 2010-09-15
ES2349131T3 (es) 2010-12-28
CN101228135B (zh) 2011-08-31
CA2614529A1 (fr) 2007-01-25
AU2006271721C1 (en) 2013-09-19
HK1115129A1 (en) 2008-11-21
TWI330636B (en) 2010-09-21
MY142861A (en) 2011-01-14
AU2006271721A1 (en) 2007-01-25
TW200745052A (en) 2007-12-16
JP5000649B2 (ja) 2012-08-15
NO340679B1 (no) 2017-05-29
EP1919878B1 (fr) 2010-09-08
US20090005383A1 (en) 2009-01-01
US7807674B2 (en) 2010-10-05
JP2009501759A (ja) 2009-01-22
CN101228135A (zh) 2008-07-23
US20070032494A1 (en) 2007-02-08
KR20080019297A (ko) 2008-03-03
RU2379295C2 (ru) 2010-01-20
IL188476A (en) 2011-10-31
IL188476A0 (en) 2008-04-13
PT1919878E (pt) 2010-11-02
AR054848A1 (es) 2007-07-18

Similar Documents

Publication Publication Date Title
CA2614529C (fr) Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone thyroidienne
US8076334B2 (en) Prodrugs of thyroid hormone analogs
US9902701B2 (en) Pyridazones and triazinones for treatment and prophylaxis of hepatitis B virus infection
TWI376374B (en) Novel coumarin derivatives with antitumor activity
TWI241295B (en) Pyridazine derivative and medicine containing the same as effect component
CN101772487A (zh) 新型化合物
WO2006106052A1 (fr) 1h-pyrazole 4-carboxylamides, preparation et utilisation de ceux-ci comme 11-beta-hydroxysteroide deshydrogenase
WO2019208635A1 (fr) Dérivé condensé de pyrimidine
JPH0971535A (ja) 医薬組成物

Legal Events

Date Code Title Description
EEER Examination request